Active Filter(s):
Details:
The company based the decision on safety information after unexpected serious adverse events, including one patient death in its Phase IIb CATALYST trial.
Lead Product(s): Inarigivir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2020